Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib

被引：31
|
作者：
Marks, Asher M. [1 ]
Bindra, Ranjit S. [2 ]
DiLuna, Michael L. [3 ]
Huttner, Anita [4 ]
Jairam, Vikram [2 ]
Kahle, Kristopher T. [3 ]
Kieran, Mark W. [5 ]
机构：
[1] Yale Univ, Sch Med, Dept Pediat Hematol Oncol, 333 Cedar St,LMP 2073, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Radiat Oncol, New Haven, CT USA
[3] Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT USA
[4] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA
[5] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA
来源：
PEDIATRIC BLOOD & CANCER | 2018年 / 65卷 / 05期
关键词：
AYA; BRAF inhibitor; BRAF V600E; CNS tumor; ganglioglioma; MEK inhibitor; STEM GANGLIOGLIOMA; DABRAFENIB; MELANOMA;
D O I：
10.1002/pbc.26969
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Efficacy of BRAF V600E targeted therapies in brain tumors harboring the mutation has been shown in several case reports and is currently being studied in larger clinical trials. Monotherapy with vemurafenib has been associated with significant side effects, including rashes, papillomas, and squamous cell carcinomas. Here we describe an adolescent female with anaplastic ganglioglioma and significant skin reaction to vemurafenib with subsequent tumor response and tolerance to the BRAF/MEK inhibitor combination of dabrafenib and trametinib without recurrence of previous reaction.
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Bayesian individual exposure estimation of dabrafenib alone or in combination with trametinib in mutated-BRAF V600E metastatic melanoma patients
    Goldwirt, Lauriane
    Pressiat, Claire
    Chami, Ichrak
    Jullien, Vincent
    Sauvageon, Helene
    Madelaine, Isabelle
    Lebbe, Celeste
    Mourah, Samia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Nonesmall-cell Lung Cancer
    Pervere, Leah M.
    Rakshit, Sagar
    Schrock, Alexa B.
    Miller, Vincent A.
    Ali, Siraj M.
    Velcheti, Vamsidhar
    [J]. CLINICAL LUNG CANCER, 2017, 18 (03) : E211 - E213
  • [33] BRAF V600E Mutation in Anaplastic Thyroid Carcinoma
    Walts, A. E.
    Pao, A.
    Bose, S.
    [J]. LABORATORY INVESTIGATION, 2014, 94 : 161A - 161A
  • [34] BRAF V600E Inhibition in Anaplastic Thyroid Cancer
    Rosove, Michael H.
    Peddi, Parvin F.
    Glaspy, John A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (07): : 684 - 685
  • [35] BRAF V600E Mutation in Anaplastic Thyroid Carcinoma
    Walts, A. E.
    Pao, A.
    Bose, S.
    [J]. MODERN PATHOLOGY, 2014, 27 : 161A - 161A
  • [36] Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
    Maurício Fernando Silva Almeida Ribeiro
    Franciele Hinterholz Knebel
    Fabiana Bettoni
    Rodrigo Saddi
    Karina Perez Sacardo
    Felipe Sales Nogueira Amorim Canedo
    João Victor Machado Alessi
    Andrea Kazumi Shimada
    José Flávio Gomes Marin
    Anamaria Aranha Camargo
    Artur Katz
    [J]. npj Precision Oncology, 5
  • [37] Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance
    Ernst, Tina
    Aebi, Stefan
    Zander, Andrea
    Zander, Thilo
    [J]. BMJ CASE REPORTS, 2022, 15 (04)
  • [38] Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
    Ali, Siraj M.
    He, Je
    Carson, Wade
    Stephens, Phil J.
    Fiorillo, Joseph
    Lipson, Doron
    Palmer, Gary A.
    Ross, Jeffrey S.
    Miller, Vincent A.
    Sharman, Jeffrey
    [J]. CASE REPORTS IN ONCOLOGY, 2014, 7 (02): : 343 - 348
  • [39] Prolonged Response Induced by Single Agent Vemurafenib in a BRAF V600E Spinal Ganglioglioma: A Case Report and Review of the Literature
    Garnier, Louis
    Ducray, Francois
    Verlut, Clotilde
    Mihai, Marcella-Ionela
    Cattin, Francoise
    Petit, Antoine
    Curtit, Elsa
    [J]. FRONTIERS IN ONCOLOGY, 2019, 9
  • [40] Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
    Silva Almeida Ribeiro, Mauricio Fernando
    Knebel, Franciele Hinterholz
    Bettoni, Fabiana
    Saddi, Rodrigo
    Sacardo, Karina Perez
    Nogueira Amorim Canedo, Felipe Sales
    Machado Alessi, Joao Victor
    Shimada, Andrea Kazumi
    Gomes Marin, Jose Flavio
    Camargo, Anamaria Aranha
    Katz, Artur
    [J]. NPJ PRECISION ONCOLOGY, 2021, 5 (01)
12345